<DOC>
	<DOC>NCT00618293</DOC>
	<brief_summary>Evaluation of efficacy by determination of transfusion requirements and safety by determination of adverse events in administration of Von Willebrand factor concentrate F VIII (Haemate).</brief_summary>
	<brief_title>Haemate HS in Patients With Severe Bleeding Undergoing Valve Replacement Due to Aortic Stenosis</brief_title>
	<detailed_description />
	<mesh_term>Constriction, Pathologic</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Blood Loss, Surgical</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>patients with isolated valvular aortic stenosis or combined aorticvalve defect with prevailing stenosis with severe bleeding during aorticvalve replacement Caucasian written informed consent (Classification of bleeding as "normal", "moderate" or "excessive" by the surgeon.Classification as excessive leads to recruitment) active endocarditis history suggestive for inherited oe acquired bleeding disorder concomitant coronary heart disease agents impairing platelet function up to 14 days before surgery Pregnancy inherited platelet function known intolerance against HAEMATE HS previous thromboembolic complications Hepatitis B, C or HIV infection previous chemotherapy emergency surgery within the last 7 days weight &lt; 50 kg and &gt; 100 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>intraoperative bleeding</keyword>
	<keyword>aortic-valve replacement</keyword>
	<keyword>aortic stenosis</keyword>
	<keyword>Von Willebrand</keyword>
	<keyword>HEAMATE</keyword>
</DOC>